ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2022
Monocytic Myeloid-Derived Suppressor Cells But Not Monocytes Predict Poor Prognosis of Acute Myeloid Leukemia
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07511062 (Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.Immunology · 2026Review
- Nested co-expression network analysis identifies compact gene clusters in a black box.Bioinformatics (Oxford, England) · 2026Article
- Article
- Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.BMC endocrine disorders · 2025Article
- Recent advances in regulatory immune cells: exploring the world beyond Tregs.Frontiers in immunology · 2025Review
- Bone marrow immune cells and drug resistance in acute myeloid leukemia.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target.Frontiers in immunology · 2025Review
- Review
- Immunotherapy in leukaemia.Acta biochimica et biophysica Sinica · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Some reports suggest that high absolute monocyte count (AMC) at diagnosis is an independent predictor of poor prognosis in acute myeloid leukemia (AML), but others disagree. Monocytic myeloid-derived suppressor cells (Mo-MDSCs) are immature monocytes. This study aimed to compare the value of monocytes and Mo-MDSCs in predicting the prognosis of AML. Materials and Methods: Peripheral blood samples from 107 newly diagnosed patients with AML and 47 healthy controls (HCs) were collected. We validated the clinical significance of AMC, monocyte count (CD14 Results: Compared with HCs, the levels of AMC, monocyte count, and Mo-MDSC count were all significantly higher among patients with AML. However, only elevated Mo-MDSC count was significantly associated with lower complete remission rate, higher relapse/refractory rate, and poorer long-term survival. Conclusion: Mo-MDSCs but not monocytes predict the poor prognosis of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.